Our Group Companies
Explore our group companies worldwide
Our Japanese company manufactures and commercialises Ursodeoxycholic acid (UDCA) for local and export markets.
Our Indian company manufactures and commercialises Ursodeoxycholic acid (UDCA) for the local market.
ABC develops and manufactures products for the pharmaceutical, nutraceutical and cosmetics markets, and provides CDMO services.
Our New Zealand company produces pharma grade cholic acid and exports a range of bile acid derivatives.
Our UK company specialises in carbohydrate chemistry providing products for R&D and contract manufacturing services.
An unmatched experience and expertise
With over 70 years of experience and 1500 world-wide employees, ICE Pharma provides both products and services to the pharmaceutical industry.
ICE Pharma is an expert in the development and manufacture of bile acid derivatives. We are a leading producer of Ursodeoxycholic Acid (UDCA) with an integrated global manufacturing network in Europe, Latin America, Asia and Oceania that serves customers in over 50 countries.
Our five R&D centres have enabled us to develop a unique and comprehensive range products including Generic APIs, Excipients, Finished Dosage Forms and New Chemical Entities.
Our Products & Services
We offer a comprehensive & unique range of products & services
We offer an extensive range of products for the pharmaceutical market including APIs, Finished Dosage Forms and Excipients.
We provide pharmaceutical contract development and manufacturing services for solid and liquid finished dosage forms and complex carbohydrates
Our range of branded nutraceutical supplements is focused on strengthening the immune system and gut health. We are also a provider of natural taurine.
We supply the academic and research communities with complex carbohydrates and novel bile acid derivatives.
Our branded natural cosmetics range is focused on skin care.
Our global footprint
Facilities & companies across the globe
ICE Pharma has an interconnected network of 7 manufacturing facilities in North and South America, Europe, Asia and Oceania through which we provide our customers with an unparalleled security of supply and a local service.
News & Articles
Stay up to date with ICE Pharma’s latest news, events & publications
ICE Pharma published the Sustainability Report 2021/2022
During 2022, ICE Pharma developed a long-term sustainability strategy and a short-term roadmap that will guide our actions for the next three years. We describe the strategic choices that...
ICE Pharma acquires Iwaki manufacturing site from Mitbubishi API corporation
We are pleased to announce that on May 2nd ICE Pharma completed the purchase of the Iwaki Ursodeoxycholic Acid (“UDCA”) manufacturing site from Mitsubishi API Corporation. This transaction represents...
Third research publication in collaboration with ICE Pharma and Ferrier Research Institute
Synthesis of Novel C/D Ring Modified Bile Acids Bile acid receptors have been identified as important targets for the development of new therapeutics to treat various metabolic and inflammatory...